{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:35:38Z","timestamp":1785306938824,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2018,7,8]],"date-time":"2018-07-08T00:00:00Z","timestamp":1531008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Accurately estimating kidney function is essential for the safe administration of renally cleared drugs such as ganciclovir. Current practice recommends adjusting renally eliminated drugs according to the Cockcroft\u2013Gault equation. There are no data on the utility of the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD\u2010EPI) equations in ganciclovir dosing. To evaluate which renal function equation best predicts ganciclovir clearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The performance of the Cockcroft\u2013Gault equation, isotope dilution mass spectrometry (IDMS)\u2010traceable 4\u2010variable MDRD study (MDRD4\u2010IDMS) equation and CKD\u2010EPI equation in determining ganciclovir clearance were assessed retrospectively in patients treated with ganciclovir from 2004\u20132015. The MDRD4\u2010IDMS and CKD\u2010EPI equations adjusted to individual body surface area (MDRD4\u2010IDMS\u00b7BSA and CKD\u2010EPI\u00b7BSA, respectively) were also evaluated. Patients with intravenous ganciclovir peak and trough concentrations in their medical records were included in the study. Ganciclovir clearance was calculated from serum concentrations using a one\u2010compartment model. The five equations were compared based on their predictive ability, the coefficient of determination, through a linear regression analysis. The results were validated in a group of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred patients were included in the final analysis. Seventy\u2010four patients were analysed in the learning group and 26 in the validation group. The coefficient of determination was 0.281 for Cockcroft\u2013Gault, 0.301 for CKD\u2010EPI\u00b7BSA, 0.308 for MDRD4\u2010IDMS\u00b7BSA, 0.324 for MDRD4\u2010IDMS and 0.360 for CKD\u2010EPI. Subgroup analysis also showed that CKD\u2010EPI is a better predictor of ganciclovir clearance. Analysis of the validation group confirmed these results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The CKD\u2010EPI equation correlates better with ganciclovir clearance than the Cockcroft\u2010Gault and MDRD4\u2010IDMS equations, even the clinical difference between the equations is scarce.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13647","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T13:00:15Z","timestamp":1527080415000},"page":"2120-2128","source":"Crossref","is-referenced-by-count":29,"title":["Comparison of the Cockcroft\u2013Gault, MDRD and CKD\u2010EPI equations for estimating ganciclovir clearance"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-3270","authenticated-orcid":false,"given":"Maria\u2010Eugenia","family":"Palacio\u2010Lacambra","sequence":"first","affiliation":[{"name":"Department of Pharmacy Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immaculada","family":"Comas\u2010Reixach","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Blanco\u2010Grau","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep\u2010Maria","family":"Su\u00f1\u00e9\u2010Negre","sequence":"additional","affiliation":[{"name":"Pharmacy Faculty University of Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Segarra\u2010Medrano","sequence":"additional","affiliation":[{"name":"Department of Nephrology Arnau de Vilanova University Hospital  Lleida Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9\u2010Bruno","family":"Montoro\u2010Ronsano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609053351007"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.177"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.12.1899"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/10.Supplement_3.S507"},{"key":"e_1_2_8_6_1","volume-title":"Cymevene\u00ae (Ganciclovir sodium for injection) label information","author":"Agencia Espa\u00f1ola del Medicamento","year":"2016"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.0525144"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.077180"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.11.1130"},{"key":"e_1_2_8_14_1","volume-title":"Guideline on the evaluation of the pharmacokinetics of the medicinal products in patients with decreased renal function","author":"EMA","year":"2015"},{"key":"e_1_2_8_15_1","volume-title":"Draft guidance for industry: pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling","author":"FDA","year":"2010"},{"key":"e_1_2_8_16_1","volume-title":"Guidance for industry: pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling","author":"FDA","year":"1998"},{"key":"e_1_2_8_17_1","unstructured":"National Kidney Disease Education Program (NKDEP) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).CKD and drug dosing: information for providers (revised Apr 2015)."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.322"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.8.776"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710223171717"},{"key":"e_1_2_8_21_1","unstructured":"BlancoA FernandezP Agull\u00f3M SomolinosM WagensteenO Pelegr\u00edMD.Comparaci\u00f3n de la Tasa de Filtraci\u00f3n Glomerular estimada (TFGe) a partir de la concentraci\u00f3n s\u00e9rica de creatinina obtenida por los m\u00e9todos de Jaff\u00e9 y Jaff\u00e9 compensado. II Congreso Nacional del Laboratorio Cl\u00ednico. A Coru\u00f1a 2008 [in Spanish]."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977213362"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2014.922865"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q757"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.03.008"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja11.11468"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0434-z"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12241"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M421"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00174-11"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05634-11"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X1404200203"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T11:33:00Z","timestamp":1695036780000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,8]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/bcp.13647"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13647","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,8]]}}}